BeiGene, Ltd.

Last price update: 21 May 24 23:00 GMT

Price:
$167.39
Open:
$168.13
Previous close:
$174.32
Day's range:
$167.39 - $171.63
Year's range:
$126.97 - $244.56
Net Income per Share:
-7.55
Price-to-Earnings ratio:
-22.17
52-week Price Range:
$155.73
Volume:
$88,431.00
Average volume:
$214,235.00

Company profile for BeiGene, Ltd.

BeiGene, Ltd. logo

BeiGene, Ltd. is a biotechnology company that focuses on developing, manufacturing and commercializing medicines worldwide. The company’s products include BRUKINSA to treat mantle cell lymphoma, Tislelizumab to treat classical Hodgkin’s lymphoma, REVLIMID to treat multiple myeloma, VIDAZA to treat myelodysplastic syndromes, XGEVA to treat giant cell tumor of bone, BLINCYTO to treat acute lymphoblastic leukemia, KYPROLIS to treat relapsed/refractory multiple myeloma, and SYLVANT to treat idiopathic multicentric castleman disease. In addition, BeiGene’s clinical development pipeline includes Zanubrutinib, a BTK inhibitor to treat lymphomas; Lifirafenib, a small molecule inhibitor to treat melanoma, NSCLC, and endometrial cancer; Sitravatinib, a multikinase inhibitor to treat NSCLC, melanoma, and other solid tumors; BGB-A333, a PD-L1 inhibitor to treat various solid tumors; Ociperlimab, a TIGIT inhibitor to treat various solid tumors; BGB-11417, a small molecule Bcl-2 inhibitor to treat mature B-cell malignancies; BGB-A445, an OX40 agonist antibody to treat solid tumors; Zanidatamab, a bispecific HER2 inhibitor to treat breast and gastric cancer; BGB-A425, a T-cell immunoglobulin and mucin-domain containing-3 inhibitor to treat various solid tumors; and BGB-15025, a small molecule inhibitor of HPK1.

BeiGene, Ltd. has achieved global recognition for its innovative technology and cutting-edge treatments. The company was founded in 2010 and is headquartered in Cambridge, Massachusetts. Since its inception, BeiGene has secured strategic collaborations with leading pharmaceutical companies, such as Shoreline Biosciences, Inc., Amgen Inc., Novartis AG and Bristol Myers Squibb Company. In addition, the company is actively pursuing the development of new medicines for the treatment of cancer and other serious diseases. BeiGene has also established several subsidiaries in China, Australia and the United States, and has planned to expand its reach to additional countries. Furthermore, BeiGene is investing significantly in research and development in order to develop new and innovative medicines that can improve the lives of patients around the world.

Stock exchanges:
NASDAQ
Sector:
Healthcare
Industries:
Biotechnology
Ticker:
BGNE
CIK:
1651308
ISIN:
US07725L1026
Website:
https://www.beigene.com
Phone:
781-801-1800
Origin:
United States
Employees:
9,000